Contract Services
The facilities’ offerings include upstream and downstream development, process design, analytical development, GMP QC testing, GMP Cell-Based Assays,...
January 18, 2024 | News
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its off-the-shelf Rep/Cap plasmid offering, designed to streamline...
January 17, 2024 | News
WuXiBodyTM has been widely adopted globally since its launch in 2018. It can effectively break through the CMC barriers for the development of many bi...
January 17, 2024 | News
Under the terms of the agreement, WuXi Biologics leverages its proprietary antibody discovery technology platforms (R in CRDMO) to discover two undisclosed...
January 11, 2024 | News
AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced plans to construct...
January 05, 2024 | News
Under the agreement, IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate (OHPASTM) Linker and novel...
January 03, 2024 | News
This expansion has been selected by the Japanese Ministry of Economy, Trade and Industry (METI) as part of its "Developing biopharmaceutical manufacturin...
December 26, 2023 | News
The newly inaugurated cGMP facility is equipped with its proprietary One-Bac 4.0 System with Sf-RVF® cell line and adheres to the NMPA, FDA and EM...
December 21, 2023 | News
Highlights: Significant improvement was assessed by both clinicians and caregivers across multiple efficacy measures Improvements were con...
December 19, 2023 | News
Atmo Biosciences, a company commercializing the world’s first ingestible gas-sensing capsule that provides insights into gut health and microbiome fu...
December 14, 2023 | News
The three-day comprehensive audit covered the CDMO site's drug substance (DS) facility, drug product (DP) facility, QC laboratories, warehouse, and utiliti...
December 07, 2023 | News
Further develops its biosafety testing laboratories to meet local demand New labs complete 2nd phase of company’s € 29 million...
November 30, 2023 | News
By leveraging WuXiUPTM, WuXi Biologics has completed its first end-to-end continuous drug substance (DS) manufacturing from perfused cell culture...
November 23, 2023 | News
WuXi XDC issued a total of 178,446,000 shares under the global offering at an offer price of HK$20.60 per share (being the high-end of the indica...
November 20, 2023 | News
Most Read
Bio Jobs
News
Editor Picks